A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes

• Status: Completed
• Trial end date: 2012-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This Phase 2 study will asses the LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with type 2 diabetes.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Esperion Therapeutics; Esperion Therapeutics, Inc.
• Treatments: 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid

Criteria

Inclusion Criteria:

• Diagnosis of type 2 diabetes meeting all of the following:

• Minimum 6 month history of diabetes prior to screening visit;

• Fasting C-peptide ≥ 0.8 ng/mL at screening visit;

• HbA1C at screening visit 7-10%;

• Fasting glucose from 140-270 mg/dL on Day -7 following washout of all glucose regulating drugs and supplements.

• BMI at screening visit from 25-35 kg/m2;

• LDL-C at screening ≥ 100 mg/dL